Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Plus Tremelimumab in Muscle-Invasive, High-Risk Urothelial Carcinoma
NCT02812420Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2017
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab and tremelimumab in urothelial carcinoma (UC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events determined by extreme toxicity. Started Mar 2017; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02812420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02812420.